Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KE1F
|
|||
| Former ID |
DNCL003455
|
|||
| Drug Name |
DFP-10917
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 3 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [2] | ||
| Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Phase 1/2 | [3] | ||
| Company |
Delta-Fly Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H12N4O4
|
|||
| Canonical SMILES |
C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)C#N
|
|||
| InChI |
1S/C10H12N4O4/c11-3-5-8(16)6(4-15)18-9(5)14-2-1-7(12)13-10(14)17/h1-2,5-6,8-9,15-16H,4H2,(H2,12,13,17)/t5-,6+,8-,9+/m0/s1
|
|||
| InChIKey |
DCYBPMFXJCWXNB-JWIUVKOKSA-N
|
|||
| CAS Number |
CAS 135598-68-4
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:145435
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA replication (DNA repli) | Target Info | Inhibitor | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03926624) Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT00824161) Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer. U.S. National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT01702155) Phase I/II Study of DFP-10917 in Patients With Acute Leukemia. U.S. National Institutes of Health. | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.